nach oben

Spektrum der Augenheilkunde

Erschienen in:

11.07.2017 | original article

Intracameral moxifloxacin for prophylaxis of postoperative endophthalmitis

verfasst von: Nedime Sahinoglu-Keskek, MD, Prof. Aysel Pelit

Erschienen in: Spektrum der Augenheilkunde | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Summary

Background

The aim of this study was to evaluate the rates of post-cataract-surgery endophthalmitis after prophylactic intracameral moxifloxacin administration.

Methods

In this retrospective descriptive study, 1013 uncomplicated cataract surgeries with intraocular lens implantation were performed between March 2009 and November 2013 by one surgeon (AP). Each patient received an intracameral injection of 0.05 ml undiluted 0.5% moxifloxacin for prophylaxis of postoperative infection.

Results

The mean follow-up of patients was 1 year (range: 2 months to 4 years), and the mean age of the patients was 64.2 years (range: 38–99 years). Of the 1013 patients, 617 (58.6%) were women. No case of endophthalmitis occurred.

Conclusion

No postoperative endophthalmitis was observed after the intracameral injection of 0.5% moxifloxacin ophthalmic solution during routine cataract surgery.

Vorheriger Artikel Postsurgical ptosis associated with intraoperative eyelid dilatability

Nächster Artikel Effektivität und Frequenz der intravitrealen Injektionstherapie bei neovaskulärer altersabhängiger Makuladegeneration im Krankenhaus Hietzing im internationalen Vergleich

Barry P, Seal DV, Gettinby G, et al. ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery: preliminary report of principal results from a Europeanmulticenter study. J Cataract Refract Surg. 2006;32:407–10.CrossRefPubMed

Endophthalmitis Study Group. European Society of Cataract & Refractive Surgeons. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2007;33:978–88.CrossRef

Frilling E, Lundström M, Stenevi U, Montan P. Six-year incidence of endophthalmitis after cataract surgery: Swedish national study. J Cataract Refract Surg. 2013;39:15–21.CrossRef

Espiritu CRG, Caparas VL, Bolinao JG. Safety of prophylactic intracameral moxifloxacin 0.5 % ophthalmic solution in cataract surgery patients. J Cataract Refract Surg. 2007;33:63–8.CrossRefPubMed

Kim SY, Park Y‑H, Lee Y‑C. Comparison of the effect of intracameral moxifloxacin, levofloxacin and cefazolin on rabbit corneal endothelial cells. Clin Experiment Ophthalmol. 2008;36:367–70.CrossRefPubMed

Lane SS, Osher RH, Masket S, Belani S. Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery. J Cataract Refract Surg. 2008;34:1451–9.CrossRefPubMed

O’Brien TP, Arshinoff SA, Mah FS. Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin. J Cataract Refract Surg. 2007;33:1790–800.CrossRefPubMed

Arbisser LB. Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery. J Cataract Refract Surg. 2008;34:1114–20.CrossRefPubMed

Matsuura K, Suto C, Akura J, Inoue Y. Bag and chamber flushing: a new method of using intracameral moxifloxacin to irrigate the anterior chamber and the area behind the intraocular lens. Graefes Arch Clin Exp Ophthalmol. 2013;251:81–7.CrossRefPubMed

10.

Kowalski RP, Romanowski EG, Mah FS, et al. Intracameral Vigamox (moxifloxacin 0.5 %) is non-toxic and effective in preventing endophthalmitis in a rabbit model. Am J Ophthalmol. 2005;140:497–504.CrossRefPubMed

11.

Stroman DW, Dajcs JJ, Cupp GA, Schlech BA. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5 %; a new topical fluoroquinolone. Surv Ophthalmol. 2005;50:16–31.CrossRef

12.

West ES, Behrens A, McDonnell PJ, et al. The incidence of endophthalmitis after cataract surgery among the U.S. Medicare population between 1994 and 2001. Ophthalmology. 2005;112:1388–94.CrossRefPubMed

13.

Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery; an evidence-based update. Ophthalmology. 2002;109:13–24, questions for CME credit request, 25–26.CrossRefPubMed

14.

Isenberg SJ, Apt L, Yoshimori R, et al. Efficacy of topical povidoneiodine during the first week after ophthalmic surgery. Am J Ophthalmol. 1997;124:31–5.CrossRefPubMed

15.

Arshinoff SA, Bastianelli PA. Incidence of postoperative endophthalmitis after immediate sequential bilateral cataract surgery. J Cataract Refract Surg. 2011;37:2105–14.CrossRefPubMed

16.

Lin M, Zhang W, Liu Y, et al. Nosocomial acute-onset postoperative endophthalmitis at a university teaching hospital in China. J Hosp Infect. 2011;79:323–7.CrossRefPubMed

17.

Ozlem TY, Necati DM, Fatma YM, et al. Are cefuroxime and vancomycin really safe on the corneal endothelial cells? Graefes Arch Clin Exp Ophthalmol. 2010;248(3):415–20.CrossRefPubMed

18.

Delyfer MN, Rougier MB, Leoni S, et al. Ocular toxicity after intracameral injection of very high doses of cefuroxime during cataract surgery. J Cataract Refract Surg. 2011;37(2):271–8.CrossRefPubMed

19.

Alfonso E, Crider J. Ophthalmic infections and their anti-infective challenges. Surv Ophthalmol. 2005;50:1–6.CrossRef

20.

Schlech BA, Alfonso E. Overview of the potency of moxifloxacin ophthalmic solution 0.5 % (Vigamox). Surv Ophthalmol. 2005;50:7–15.CrossRef

21.

Trinkhaus-Randall V, Edelhauser HF, Leibowitz HM, Freddo TF. Corneal structure and function. In: Leibowitz HM, Waring GO III, editors. Corneal disorders; clinical diagnosis and management, 2nd edn. Philadelphia PA: WB Saunders; 1998. pp. 21–7.

22.

Shorstein NH, Winthrop KL, Herrinton LJ. Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a Northern California eye department. J Cataract Refract Surg. 2013;39(1):8–14.CrossRefPubMed

23.

Galvis V, Tello A, Sánchez MA, Camacho PA. Cohort study of intracameral moxifloxacin in postoperative endophthalmitis prophylaxis. Ophthalmol Eye Dis. 2014;6:1–4.PubMedPubMedCentral

24.

Haripriya A, Chang DF, Namburar S, Smita A, Ravindran RD. Efficacy of Intracameral moxifloxacin endophthalmitis prophylaxis at aravind eye hospital. Ophthalmology. 2016;123(2):302–8.CrossRefPubMed

25.

Haripriya A, Chang DF, Ravindran RD. Endophthalmitis reduction with intracameral moxifloxacin prophylaxis: analysis of 600 000 surgeries. Ophthalmology. 2017;124(6):768–75.CrossRefPubMed

26.

Zhou AX, Messenger WB, Sargent S, Ambati BK. Safety of undiluted intracameral moxifloxacin without postoperative topical antibiotics in cataract surgery. Int Ophthalmol. 2016;36(4):493–8.CrossRefPubMed

Titel: Intracameral moxifloxacin for prophylaxis of postoperative endophthalmitis
verfasst von: Nedime Sahinoglu-Keskek, MD
Prof. Aysel Pelit
Publikationsdatum: 11.07.2017
Verlag: Springer Vienna
Erschienen in: Spektrum der Augenheilkunde / Ausgabe 5/2017
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI: https://doi.org/10.1007/s00717-017-0350-0

Springer Medizin Österreich

Summary

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

Schlaglicht Augenheilkunde: Ophthalmopathologie

Photorefraktive Keratektomie in Kombination mit Hornhautquervernetzung – eine Alternative zur Keratoplastik bei Keratokonus?

Subfoveal fluid and intraretinal edema 2 days after uneventful phacoemulsification

Geriatric Orthoptics and Non-Paretic Diplopia in Adults

Postsurgical ptosis associated with intraoperative eyelid dilatability

Effektivität und Frequenz der intravitrealen Injektionstherapie bei neovaskulärer altersabhängiger Makuladegeneration im Krankenhaus Hietzing im internationalen Vergleich